Product description:Erlotinib monotherapy applicable to at least one of previously treated locally advanced or metastatic chemotherapy after the failure of non-small cell lung cancer (NSCLC). More than two centers, Ⅲ trial randomized, placebo-controlled, showed that erlotinib combined with platinum-containing chemotherapy (carboplatin + paclitaxel; or gemcitabine + cisplatin) as locally advanced or metastatic NSCLC patients with first-line treatment, relative to platinum-containing chemotherapy alone did not increase the clinical benefit and is not recommended first-line treatment for the above conditions.
Send inquiry online For more product information and prices
(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)
After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone SwissEmail: [email protected]
Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: